Bang Y J, Van C E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial [J]. Lancet, 2010, 376(9742): 687-697.
[1]
Bang Y J, Van C E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial [J]. Lancet, 2010, 376(9742): 687-697.
[2]
Kang Y K, Rha S Y, Tassone P, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer [J]. Br J Cancer, 2014, 111(4): 660-666.
[2]
Kang Y K, Rha S Y, Tassone P, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer [J]. Br J Cancer, 2014, 111(4): 660-666.
[3]
Satoh T, Xu R H, Chung H C, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study [J]. J Clin Oncol, 2014, 32(19): 2039-2049.
[3]
Satoh T, Xu R H, Chung H C, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study [J]. J Clin Oncol, 2014, 32(19): 2039-2049.
[4]
Hecht J R, Bang Y J, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO013/LOGiC Trial [J]. J Clin Oncol, 2013, 31 (Suppl): abstract LBA4001.
[5]
Lordick F, Kang Y K, Chung H C, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial [J]. Lancet Oncol, 2013,14 (6):490-499.
[4]
Hecht J R, Bang Y J, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO013/LOGiC Trial [J]. J Clin Oncol, 2013, 31 (Suppl): abstract LBA4001.
[5]
Lordick F, Kang Y K, Chung H C, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial [J]. Lancet Oncol, 2013,14 (6):490-499.
[6]
Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial [J], Lancet Oncol, 2013, 14 (6):481-489.
[7]
Ohtsu A, Shah M A, Van Cutsem E, et al. Bevacizumab in combinationwith chemotherapy as first-line therapy in advanced gastric cancer: arandomized, double-blind, placebo-controlled phase III study [J]. Clin Oncol , 2011, 29(30):3968-3976.
[8]
Shen L, Li J, Xu J, et al. Bevacizumab plus capecitabine and cisplatinin Chinese patients with inoperable locally advanced or metastaticgastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study) [J]. Gastric Cancer, 2015,18(1):168-176.
[6]
Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial [J], Lancet Oncol, 2013, 14 (6):481-489.
[9]
Fuchs C S, Tomasek J, Yong C J, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J]. Lancet, 2014, 383(9911):31-39.
[7]
Ohtsu A, Shah M A, Van Cutsem E, et al. Bevacizumab in combinationwith chemotherapy as first-line therapy in advanced gastric cancer: arandomized, double-blind, placebo-controlled phase III study [J]. Clin Oncol , 2011, 29(30):3968-3976.
[10]
Wilke H, Van Cutsem E, Oh S C, et al .Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind, randomised phase 3 trial [J].Lancet Oncol, 2014, 15(11): 1224-1235.
[8]
Shen L, Li J, Xu J, et al. Bevacizumab plus capecitabine and cisplatinin Chinese patients with inoperable locally advanced or metastaticgastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study) [J]. Gastric Cancer, 2015,18(1):168-176.
[11]
Ohtsu A, Ajani J A, Bai Y X, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase Ⅲ GRANITE-1 study [J]. J Clin Oncol, 2013, 31(31):3935-3943.
[9]
Fuchs C S, Tomasek J, Yong C J, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J]. Lancet, 2014, 383(9911):31-39.
[10]
Wilke H, Van Cutsem E, Oh S C, et al .Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind, randomised phase 3 trial [J].Lancet Oncol, 2014, 15(11): 1224-1235.
[11]
Ohtsu A, Ajani J A, Bai Y X, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase Ⅲ GRANITE-1 study [J]. J Clin Oncol, 2013, 31(31):3935-3943.
[12]
Oliner K S, Tang R, Anderson A, et al. Evaluanon of MET pathway biomarkers in a Phase II study of rilotumumab(R, AMG102) or placebo(P) in combination with epirubicin,cisplatin,and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer [J]. J Clin Oncol, 2012, 30(suppl): a4005.
[13]
Merchant M, Ma X, Maun H R, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent [J]. Proc Natl Acad Sci USA, 2013, 110(32): E2987-2996.
[12]
Oliner K S, Tang R, Anderson A, et al. Evaluanon of MET pathway biomarkers in a Phase II study of rilotumumab(R, AMG102) or placebo(P) in combination with epirubicin,cisplatin,and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer [J]. J Clin Oncol, 2012, 30(suppl): a4005.
[13]
Merchant M, Ma X, Maun H R, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent [J]. Proc Natl Acad Sci USA, 2013, 110(32): E2987-2996.
[14]
Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial [J]. Clin Cancer Res, 2002, 8(6): 1767-1771.
[15]
Guo-Qing Z, Hong Z, Jian-Yu W, et al. Prolonged overall survival in gastric cancer patients after adoptive immunotherapy [J]. World J Gastroenterol, 2015, 21(9): 2777-2785.
[14]
Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial [J]. Clin Cancer Res, 2002, 8(6): 1767-1771.
[16]
Masuzawa T, Fujiwara Y, Okada K, et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer [J]. Int J Oncol, 2012, 41(4): 1297-1304.
[15]
Guo-Qing Z, Hong Z, Jian-Yu W, et al. Prolonged overall survival in gastric cancer patients after adoptive immunotherapy [J]. World J Gastroenterol, 2015, 21(9): 2777-2785.
[17]
Cancer Genome Atlas Research Network. Comprehesive molecular characterization of gastric adenocarcinoma [J]. Nature, 2014, 513(7517): 202-209.
[18]
Hans-Jürgen B.Isolation and culturing of highly polarized primary epithelial cells from normal human stomach (antrum) as spheroid-like vesicles [J]. Methods in Cell Science, 1997, 19(3):169-178.
[19]
Xingnan L, Lincoln N, Akifumi O, et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture [J]. Nature Medicine, 2014, 20(7):769-777.
[16]
Masuzawa T, Fujiwara Y, Okada K, et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer [J]. Int J Oncol, 2012, 41(4): 1297-1304.
[17]
Cancer Genome Atlas Research Network. Comprehesive molecular characterization of gastric adenocarcinoma [J]. Nature, 2014, 513(7517): 202-209.
[18]
Hans-Jürgen B.Isolation and culturing of highly polarized primary epithelial cells from normal human stomach (antrum) as spheroid-like vesicles [J]. Methods in Cell Science, 1997, 19(3):169-178.
[19]
Xingnan L, Lincoln N, Akifumi O, et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture [J]. Nature Medicine, 2014, 20(7):769-777.
2015, Vol. 26 
